Cerebrospinal fluid: identification of diagnostic markers for schizophrenia

No abstract is available for this paper.

• Publication year

  2008

• Venue

  Expert Review of Molecular Diagnostics

• Publication date

  2008-03-01

• Fields of study

  Medicine

• Identifiers
  DOI 10.1586/14737159.8.2.209PMID 18366307
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Differential effects of SNAP-25 deletion on Ca2+ -dependent and Ca2+ -independent neurotransmission.

  2007cited by this paper
• d-Amino acid oxidase and serine racemase in human brain: normal distribution and altered expression in schizophrenia

  2007cited by this paper
• A genetic variant of the serine racemase gene is associated with schizophrenia.

  2007cited by this paper
• CSF biomarker discovery using label-free nano-LC-MS based proteomic profiling: technical aspects.

  2007cited by this paper
• Serum S100B and antioxidant enzymes in bipolar patients.

  2007cited by this paper
• Increased S100B protein serum levels in psoriasis.

  2007cited by this paper
• Haloperidol and clozapine differentially regulate signals upstream of glycogen synthase kinase 3 in the rat frontal cortex

  2007cited by this paper
• CSF Metabolic and Proteomic Profiles in Patients Prodromal for Psychosis

  2007cited by this paper
• Elevated S100B levels do not correlate with the severity of encephalopathy during sepsis.

  2007cited by this paper
• A CSF and postmortem brain study of D-serine metabolic parameters in schizophrenia.

  2007cited by this paper
• Risk factors for schizophrenia--all roads lead to dopamine.

  2007cited by this paper
• Label-free LC-MS/MS quantitative proteomics for large-scale biomarker discovery in complex samples.

  2007cited by this paper
• Comparative proteome analysis revealed up-regulation of transthyretin in rat brain under chronic clozapine treatment.

  2007cited by this paper
• Low cerebrospinal fluid transthyretin levels in depression: correlations with suicidal ideation and low serotonin function.

  2006cited by this paper
• Dysregulation of retinoid transporters expression in body fluids of schizophrenia patients.

  2006cited by this paper
• Metabolic Profiling of CSF: Evidence That Early Intervention May Impact on Disease Progression and Outcome in Schizophrenia

  2006cited by this paper
• Disease Biomarkers in Cerebrospinal Fluid of Patients with First-Onset Psychosis

  2006cited by this paper
• Serine racemase protein expression in cortex and hippocampus in schizophrenia

  2006cited by this paper
• Increased cerebrospinal fluid and serum levels of S100B in first-onset schizophrenia are not related to a degenerative release of glial fibrillar acidic protein, myelin basic protein and neurone-specific enolase from glia or neurones

  2006cited by this paper
• Insulin receptor deficits in schizophrenia and in cellular and animal models of insulin receptor dysfunction.

  2006cited by this paper
• A proteome analysis of the anterior cingulate cortex gray matter in schizophrenia

  2006cited by this paper
• Reduced D-serine to total serine ratio in the cerebrospinal fluid of drug naive schizophrenic patients.

  2005cited by this paper
• Antipsychotics alter the protein expression levels of beta-catenin and GSK-3 in the rat medial prefrontal cortex and striatum.

  2005cited by this paper
• The SNAP-25 gene may be associated with clinical response and weight gain in antipsychotic treatment of schizophrenia.

  2005cited by this paper
• Raised serum S100B levels after acute bone fractures without cerebral injury.

  2005cited by this paper
• Proteomics analysis of prefractionated human lumbar cerebrospinal fluid

  2005cited by this paper
• Increased serum S100B in elderly, chronic schizophrenic patients: negative correlation with deficit symptoms.

  2005cited by this paper
• Low GSK-3β in schizophrenia as a consequence of neurodevelopmental insult

  2005cited by this paper
• D-serine efficacy as add-on pharmacotherapy to risperidone and olanzapine for treatment-refractory schizophrenia.

  2005cited by this paper
• Dysfunction of Glia-Neuron Communication in Pathophysiology of Schizophrenia

  2005cited by this paper
• GSK-3beta in cerebrospinal fluid of schizophrenia patients.

  2004cited by this paper
• S100B in schizophrenic psychosis.

  2004cited by this paper
• Glutamate as a therapeutic target in psychiatric disorders

  2004cited by this paper
• CHANGES IN CSF S100B AND CYTOKINE CONCENTRATIONS IN EARLY-PHASE SEVERE TRAUMATIC BRAIN INJURY

  2004cited by this paper
• Convergent evidence for impaired AKT1-GSK3β signaling in schizophrenia

  2004cited by this paper
• GSK-3β in cerebrospinal fluid of schizophrenia patients

  2004cited by this paper
• Protein profiling of human postmortem brain using 2-dimensional fluorescence difference gel electrophoresis (2-D DIGE)

  2004cited by this paper
• Glutamate Hypothesis of Schizophrenia and Approach for Possible Therapeutic Drugs

  2004cited by this paper
• Glial cell dysfunction in schizophrenia indicated by increased S100B in the CSF

  2004cited by this paper
• GSK-3 parameters in postmortem frontal cortex and hippocampus of schizophrenic patients.

  2004cited by this paper
• Lack of effect of mood stabilizers or neuroleptics on GSK-3 protein levels and GSK-3 activity.

  2003cited by this paper
• Glycogen synthase kinase (GSK)-3beta levels and activity in a neurodevelopmental rat model of schizophrenia.

  2003cited by this paper
• Psychosis as a state of aberrant salience: a framework linking biology, phenomenology, and pharmacology in schizophrenia.

  2003cited by this paper
• Decreased serum levels of D-serine in patients with schizophrenia: evidence in support of the N-methyl-D-aspartate receptor hypofunction hypothesis of schizophrenia.

  2003cited by this paper
• S100B in brain damage and neurodegeneration

  2003cited by this paper
• Cerebrospinal fluid analysis.

  2003cited by this paper
• Elevated cerebrospinal fluid SNAP-25 in schizophrenia.

  2003cited by this paper
• Presynaptic proteins in the prefrontal cortex of patients with schizophrenia and rats with abnormal prefrontal development

  2003cited by this paper
• Serum S100B is increased during early treatment with antipsychotics and in deficit schizophrenia.

  2003cited by this paper
• Micrometer-sized particles in cerebrospinal fluid (CSF) in patients with schizophrenia.

  2002cited by this paper
• Genetic and physiological data implicating the new human gene G72 and the gene for D-amino acid oxidase in schizophrenia.

  2002cited by this paper
• Analysis of the human lumbar cerebrospinal fluid proteome

  2002cited by this paper
• Neuregulin 1 and susceptibility to schizophrenia.

  2002cited by this paper
• GSK-3 parameters in lymphocytes of schizophrenic patients.

  2002cited by this paper
• Increased S100B blood levels in unmedicated and treated schizophrenic patients are correlated with negative symptomatology

  2001cited by this paper
• Altered levels of the synaptosomal associated protein SNAP-25 in hippocampus of subjects with mood disorders and schizophrenia

  2001cited by this paper
• Low GSK-3 activity in frontal cortex of schizophrenic patients.

  2001cited by this paper
• The emerging role of glutamate in the pathophysiology and treatment of schizophrenia.

  2001cited by this paper
• Lamina-specific deficits in parvalbumin-immunoreactive varicosities in the prefrontal cortex of subjects with schizophrenia: evidence for fewer projections from the thalamus.

  2001cited by this paper
• Increased serum S100B protein in schizophrenia: a study in medication-free patients.

  2001cited by this paper
• GABAergic local circuit neurons and prefrontal cortical dysfunction in schizophrenia.

  2000cited by this paper
• Levels of mRNAs encoding synaptic vesicle and synaptic plasma membrane proteins in the temporal cortex of elderly schizophrenic patients.

  2000cited by this paper
• Twin studies of schizophrenia: from bow-and-arrow concordances to star wars Mx and functional genomics.

  2000cited by this paper
• Decreased S100-beta protein in schizophrenia: preliminary evidence.

  2000cited by this paper
• Low GSK-3beta immunoreactivity in postmortem frontal cortex of schizophrenic patients.

  2000cited by this paper
• Novel neurotransmitters and their neuropsychiatric relevance.

  2000cited by this paper
• Stereological studies of the schizophrenic brain.

  2000cited by this paper
• Low levels of transthyretin in the CSF of depressed patients.

  1999cited by this paper
• Elevated plasma levels of S-100b protein in schizophrenic patients.

  1999cited by this paper
• Alterations in synaptic proteins and their encoding mRNAs in prefrontal cortex in schizophrenia: a possible neurochemical basis for ‘hypofrontality’

  1999cited by this paper
• CSF SNAP-25 in Schizophrenia and Bipolar Illness A Pilot Study

  1999cited by this paper
• First-episode schizophrenia with long duration of untreated psychosis: Pathways to care

  1998cited by this paper
• D-serine added to antipsychotics for the treatment of schizophrenia.

  1998cited by this paper
• The role of thyroid hormones in depression.

  1998cited by this paper
• Altered levels of the synaptosomal associated protein SNAP-25 in schizophrenia.

  1998cited by this paper
• SNAP-25 deficit and hippocampal connectivity in schizophrenia.

  1998cited by this paper
• Jugular venous and arterial concentrations of serum S-100B protein in patients with severe head injury: a pilot study

  1998cited by this paper
• Schizophrenia and glutamatergic transmission.

  1998cited by this paper
• Relationship of neuron specific enolase and protein S-100 concentrations in systemic and jugular venous serum to injury severity and outcome after traumatic brain injury.

  1998cited by this paper
• S-100 protein: serum marker of focal brain damage after ischemic territorial MCA infarction.

  1997cited by this paper
• Increased concentrations of presynaptic proteins in the cingulate cortex of subjects with schizophrenia.

  1997cited by this paper
• Leakage of brain-originated proteins in peripheral blood: temporal profile and diagnostic value in early ischemic stroke.

  1997cited by this paper
• The S-100: a protein family in search of a function.

  1995cited by this paper
• γ‐Glutamylglutamine and Taurine Concentrations Are Decreased in the Cerebrospinal Fluid of Drug‐Naive Patients with Schizophrenic Disorders

  1995cited by this paper
• Glutamate receptor dysfunction and schizophrenia.

  1995cited by this paper
• The Biochemistry of Neurotransmitter Secretion(*)

  1995cited by this paper
• Overexpression of the Neurotrophic Cytokine S100β in Human Temporal Lobe Epilepsy

  1995cited by this paper
• Characteristics of Outcome in Schizophrenia at 13 Years

  1995cited by this paper
• Thyroid function screening in newly admitted psychiatric inpatients.

  1994cited by this paper
• S100 beta expression in Alzheimer's disease: relation to neuropathology in brain regions.

  1994cited by this paper
• Recent advances in the phencyclidine model of schizophrenia.

  1991cited by this paper
• Evidence for neurodevelopment disturbances in anterior cingulate cortex of post-mortem schizophrenic brain.

  1991cited by this paper
• The identification of a novel synaptosomal-associated protein, SNAP-25, differentially expressed by neuronal subpopulations

  1989cited by this paper
• Thyroid function screening in new psychiatric admissions.

  1982cited by this paper

• The Role of Extracellular Vesicles and Microparticles in Central Nervous System Disorders: Mechanisms, Biomarkers, and Therapeutic Potential

  2024cites this paper
• Schizophrenia: Current Progress and New Treatment Perspective

  2022cites this paper
• Cerebrospinal fluid BDNF pro-peptide levels in major depressive disorder and schizophrenia.

  2019cites this paper
• PDW and RDW are new parameters for bipolar episodes and unipolar depression

  2019cites this paper
• No major influence of regular tobacco smoking on cerebrospinal fluid monoamine metabolite concentrations in patients with psychotic disorder and healthy individuals.

  2018cites this paper
• The correlation between plasma brain-derived neurotrophic factor and cognitive function in bipolar disorder is modulated by the BDNF Val66Met polymorphism

  2016cites this paper
• Identification of amyotrophic lateral sclerosis disease mechanisms by cerebrospinal fluid proteomic profiling

  2016cites this paper
• Cortisol and inflammation in delirium and long-term cognitive decline after hip fracture

  2016cites this paper
• Biomarkers of psychiatric diseases: current status and future prospects.

  2015cites this paper
• Correlation of plasma brain‐derived neurotrophic factor and metabolic profiles in drug‐naïve patients with bipolar II disorder after a twelve‐week pharmacological intervention

  2015cites this paper
• Total protein is an effective loading control for cerebrospinal fluid western blots.

  2015cites this paper
• Psychiatric patient stratification using biosignatures based on cerebrospinal fluid protein expression clusters.

  2013cites this paper
• Schizophrenia: Metabolic aspects of aetiology, diagnosis and future treatment strategies

  2013cites this paper
• Microscopic Particles in Two Fractions of Fresh Cerebrospinal Fluid in Twins with Schizophrenia or Bipolar Disorder and in Healthy Controls

  2012cites this paper
• Rosiglitazone treatment reversed depression- but not psychosis-like behavior of db/db diabetic mice

  2012cites this paper
• Disease and genetic contributions toward local tissue volume disturbances in schizophrenia: A tensor‐based morphometry study

  2012cites this paper
• Revisiting Thyroid Hormones in Schizophrenia

  2012cites this paper
• Cerebrospinal fluid biomarker candidates of schizophrenia: where do we stand?

  2012cites this paper
• Plasma BDNF Levels Vary in Relation to Body Weight in Females

  2012cites this paper
• Use of cerebrospinal fluid biomarkers in clinical trials for schizophrenia and depression.

  2012cites this paper
• Progress in defining the biological causes of schizophrenia

  2011cites this paper
• Impact of Insulin Resistance on Behavioral and Neurochemical Deficits in db/db Mice

  2011cites this paper
• Developing predictive CSF biomarkers-a challenge critical to success in Alzheimer's disease and neuropsychiatric translational medicine.

  2011cites this paper
• A Systematic Literature Review of Cerebrospinal Fluid Biomarkers in Delirium

  2011cites this paper
• Decreased BDNF levels in CSF of drug-naive first-episode psychotic subjects: correlation with plasma BDNF and psychopathology.

  2010cites this paper
• An inverse relationship between cortisol and BDNF levels in schizophrenia: data from human postmortem and animal studies.

  2010cites this paper
• Neurobehavioral deficits in db/db diabetic mice.

  2010cites this paper
• Diagnosis of Complex Diseases

  2010cites this paper